Log in with your email address username.


[Comment] Are all drug-eluting stents created equal?

Non-inferiority trials with combined clinical endpoints in allcomer populations were suggested as a compromise between premarket assessments and speed of innovation.1 However, it is important to remain aware of the limitations of the information provided by these trials. In The Lancet, Clemens von Birgelen and colleagues2 report their comparison of two highly regarded drug-eluting stents in clinical use (the Resolute Onyx and the Orsiro stents) in a population of 2488 allcomers. The primary endpoint was target vessel failure, a hierarchical combination of safety endpoints (cardiac death or target vessel myocardial infarction) with an efficacy endpoint (target vessel revascularisation) at 1 year.